Navigation Links
A new generation of rapid-acting antidepressants?
Date:3/1/2010

Philadelphia, PA, 1 March 2010 - Conventional antidepressant treatments generally require three to four weeks to become effective, thus the discovery of treatments with a more rapid onset is a major goal of biological psychiatry. The first drug found to produce rapid improvement in mood was the NMDA glutamate receptor antagonist, ketamine.

In a new issue of Biological Psychiatry, published by Elsevier, researchers from the National Institutes of Health report that another medication, scopolamine, also appears to produce replicable rapid improvement in mood. Scopolamine temporarily blocks the muscarinic cholinergic receptor, thought to be overactive in people suffering from depression.

Drs. Wayne Drevets and Maura Furey recruited outpatients with major depressive disorder who were randomly assigned to receive placebo and then scopolamine treatment, or vice versa, in a double-blinded design so that neither the researchers nor the patients knew which treatment they were receiving.

"Scopolamine was found to reduce symptoms of depression within three days of the first administration. In fact, participants reported that they experienced relief from their symptoms by the morning after the first administration of drug," explained Dr. Furey. "Moreover, one-half of participants experienced full symptom remission by the end of the treatment period. Finally, participants remained well during a subsequent placebo period, indicating that the antidepressant effects persist for at least two weeks in the absence of further treatment."

The efficacy of scopolamine is very interesting because the potent blockade of muscarinic receptors was a property of tricyclic antidepressant medications, the oldest type of antidepressants. With these medications, the muscarinic receptor blockade was mostly viewed as the cause of unwanted side effects, such as constipation, sedation, and memory impairments. Newer antidepressants, such as serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, were explicitly designed to avoid blocking muscarinic receptors. Yet, the current data raise the possibility that this strategy may have increased safety and tolerability of these medications at the expense of providing effective and timely relief for depression symptoms.

Dr. John Krystal, Editor of Biological Psychiatry, commented that these findings "have the potential to raise expectations for new antidepressant treatments. Three-to-six weeks is a long time to wait for depression symptoms to be alleviated. Depressed people describe their emotional state using terms like 'agony' and others compare their condition to 'living in hell'. Further, depression is a life-threatening condition for some, preventing them from performing basic self-care functions or causing them to exhibit self-destructive behavior."

Although these findings open the door to a conceptually different approach to the treatment of depression, it remains to be seen whether rapid acting antidepressant effects will be viable clinically. One could imagine that they might mitigate hospitalization in some patients and enhance the overall effectiveness of the treatment of depression. However, this possibility remains to be demonstrated empirically in studies that show that a rapid-acting antidepressant treatment can be smoothly transitioned to definitive long-term treatment for depression.


'/>"/>

Contact: Maureen Hunter
m.hunter@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
2. MSAs Next-Generation Breathing Apparatus for Firefighters First to Receive Full NFPA Approval
3. Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration
4. VIDEO from Medialink and Siemens: The Next Generation Allergy Test - Nothing to Sneeze At
5. Sentillion Introduces Affordable Next Generation Healthcare Single Sign-On Solution Called expreSSO(TM)
6. Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas
7. Smithfield(R) LEAN GENERATION(R) Announces DELI FOR THE CURE(TM)
8. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
9. $37 million financing for company based on macular degeneration research
10. Model to study age-related macular degeneration could pave way for better treatment
11. Starion Instruments Launches Next-Generation Tissue Ligating Shears at the American College of Surgeons Clinical Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... San Francisco, CA (PRWEB) , ... February 27, ... ... Area center for hair transplantation therapy, is proud to announce a new informational ... popular hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, A' Design ... Edition of International Social Design Awards. , The 7th A' Social Design ... Governments and Institutions worldwide with realized projects and conceptual works. , The first ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a ... Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based on ... IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales process ...
(Date:2/26/2017)... Miami, Florida (PRWEB) , ... February 26, 2017 ... ... risk of Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according ... Disorders Congress. , Previous studies have provided evidence of a link between pesticides ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Medical information ... to increase their self-service capabilities to manage inquiries ... (HCPs). New research from consulting leader ... have developed self-service website portals where HCPs can ... just one of many findings to emerge from ...
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2015 through 2022. Also, ... data and analytics are derived from primary and secondary research. ...
(Date:2/24/2017)... from Pharma To Market Pty Ltd and Ador Consulting Pte Ltd ... founding of Pharma To Market Pte Ltd, based in ... announce their expansion into Asia with the ... company are delighted to appoint Joelle Chia , former owner ... based entity. Joelle brings with her an extensive business network ...
Breaking Medicine Technology: